State Street’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-137,219
| Closed | -$206K | – | 4789 |
|
|
2023
Q1 | $206K | Buy |
137,219
+27,900
| +26% | +$37.6K | ﹤0.01% | 4069 |
|
|
2022
Q4 | $109K | Hold |
109,319
| – | – | ﹤0.01% | 4347 |
|
|
2022
Q3 | $197K | Hold |
109,319
| – | – | ﹤0.01% | 4149 |
|
|
2022
Q2 | $317K | Sell |
109,319
-413,838
| -79% | -$1.02M | ﹤0.01% | 4008 |
|
|
2022
Q1 | $1.44M | Buy |
523,157
+7,968
| +2% | +$25.1K | ﹤0.01% | 3683 |
|
|
2021
Q4 | $2.4M | Sell |
515,189
-999,528
| -66% | -$6.25M | ﹤0.01% | 3583 |
|
|
2021
Q3 | $12.9M | Sell |
1,514,717
-716,507
| -32% | -$10.1M | ﹤0.01% | 2735 |
|
|
2021
Q2 | $36.6M | Buy |
2,231,224
+42,870
| +2% | +$866K | ﹤0.01% | 2078 |
|
|
2021
Q1 | $48.3M | Buy |
2,188,354
+1,211,294
| +124% | +$33M | ﹤0.01% | 1772 |
|
|
2020
Q4 | $30.2M | Buy |
977,060
+619,597
| +173% | +$15.7M | ﹤0.01% | 1973 |
|
|
2020
Q3 | $7.26M | Buy |
357,463
+98,780
| +38% | +$1.73M | ﹤0.01% | 2611 |
|
|
2020
Q2 | $3.97M | Buy |
258,683
+55,528
| +27% | +$640K | ﹤0.01% | 2873 |
|
|
2020
Q1 | $1.57M | Sell |
203,155
-197
| -0.1% | -$2.41K | ﹤0.01% | 3154 |
|
|
2019
Q4 | $2.9M | Buy |
203,352
+36,718
| +22% | +$568K | ﹤0.01% | 3104 |
|
|
2019
Q3 | $2.5M | Buy |
166,634
+151,934
| +1,034% | +$2.37M | ﹤0.01% | 3139 |
|
|
2019
Q2 | $152K | Buy |
+14,700
| New | +$235K | ﹤0.01% | 3630 |
|
State Street's TCRR Position: Q2 2023 in Review
State Street sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 137,219 shares — an estimated $206K sold.
State Street first reported a position in TCRR in Q2 2019 and held it in 16 quarters. The position peaked at $48.3M in Q1 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- State Street reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- State Street sold 137,219 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $206K.
- State Street first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- State Street's TCR2 Therapeutics Inc. Common Stock position peaked at $48.3M in Q1 2021.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.